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Clinical and biological aspects of restrictive anorexia nervosa (R-AN) are well documented.
More than 10,000 articles since 1911 and more than 600 in 2013 have addressed R-AN psy-
chiatric, somatic, and biological aspects. Genetic background, ineffectiveness of appetite
regulating hormones on refeeding process, bone loss, and place of amenorrhea in the
definition are widely discussed and reviewed. Oppositely, constitutional thinness (CT) is
an almost unknown entity. Only 32 articles have been published on this topic since 1953.
Similar symptoms associating low body mass index, low fat, and bone mass are reported in
both CT and R-AN subjects. Conversely, menses are preserved in CT women and almost
the entire hormonal profile is normal, except for leptin and PYY. The aim of the present
review is to alert the clinician on the confusing clinical presentation of these two situa-
tions, a potential source of misdiagnosis, especially since R-AN definition has changed in
DSM5.
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INTRODUCTION
In a young population of women, between 15 and 30 years old, a
low body mass index (BMI) associated with apparent healthy state
suggests that the diagnosis of anorexia nervosa (AN). For the same
age range, other etiologies of starvation are associated with spe-
cific symptoms leading to obvious diagnosis of blood or oncologic
pathologies, digestive absorption disorders.
Although restrictive anorexia nervosa (R-AN) definition
reported in the “diagnostic and statistical manual of mental dis-
orders” (DSM) is in perpetual evolution, diagnosis remains easy
for an experienced clinician. The last issue, DSM5, was published
in 2013 (1). Previous DSM IV definition (2) included some psy-
chological elements in the diagnosis such as “refusal to maintain a
normal BMI for their age and height, weight loss leading to main-
tenance of body weight <85% of that expected, fearful of even
the slightest weight gain and takes all precautionary measures to
avoid weight gain and becoming overweight and disturbance in
the way one’s body weight or shape is experienced, undue influ-
ence of body weight or shape on self-evaluation, or denial of the
seriousness of the current low body weight.” Amenorrhea, i.e.,
the absence of at least three consecutive menstrual cycles, was
the only somatic symptom included in the DSM IV definition.
In R-AN women, amenorrhea is related to a blunted/hibernating
hypothalamic–pituitary–gonadal (HPG) axis activity. This crite-
rion cannot be applied in pre-menarchal females, females taking
oral contraceptives, post-menopausal females, or in case of delayed
menarche. Moreover, male gonadal axis status was not mentioned
in DSM IV definition. Giving these limitations, a psychiatric task-
force developed a new wide definition meant to be relevant for
both genders. Thus, amenorrhea symptom was removed from the
current DSM5 definition, entirely based on psychiatric symptoms
(1). Major consequences of this truncated definition are further
discussed as it can lead to misdiagnosis in front of a thin woman.
DIFFERENCES BETWEEN ANOREXIA NERVOSA AND
CONSTITUTIONAL THINNESS
In a similar population of women, a low BMI associated with
apparent healthy state could also suggests that the diagnosis of a
not yet well-known entity called constitutional thinness (CT). This
natural and physiological low BMI (<18.5 kg/m2) state is asso-
ciated with preserved menses (without contraceptive treatment)
and reproductive function leading to constitutional thin families.
CT prevalence is unknown in the developed world. These sub-
jects want to gain weight and often consult in this perspective.
We recently showed that they failed to gain weight in a controlled
overfeeding study (3). Opposite to the presence of amenorrhea
that advocates for a diagnosis of R-AN, the absence of amenorrhea
advocates for a diagnosis of CT.
Thinness is defined by the World Health Organization which
specified three levels of underweight for BMI <18.5 kg/m2 (4).
Thinness is the only resemblance between R-AN and CT. Indeed,
despite the same BMI as AN, CT subjects do not exhibit any typ-
ical clinical features such as amenorrhea, fear of weight gain, or
hormonal abnormalities commonly seen in R-AN patients.
This review summarizes the main features opposing R-AN and
CT including nutritional markers, bone loss physiology, appetite
regulating hormones, and how the DSM5 definition can lead to
misdiagnoses between those two etiologies of thinness. The results
published by our group come from a large cohort of more than
600 R-AN and 100 CT.
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Hormonal abnormalities data about R-AN reported so far in
literature are commonly accepted and have been showed and
published many times by different teams. Most of them are under-
nutrition markers such as low free-T3 (5, 6), low IGF-1, and
elevated GH displaying a GH resistance (7), elevated SHBG (8),
and blunted leptin reflecting a decreased fat mass (9). These bio-
logical features are adaptive to food restriction and hormonal levels
return within normal range after refeeding (10, 11). In 2010, we
published biological data on a large R-AN cohort of 200 patients.
Despite a correlation between BMI and five specific nutritional or
hormonal parameters including leptin, GH, cortisol, free-T3, and
IGF-1, we noticed a large inter-individual heterogeneity of these
parameters (12). In CT matched for BMI and gender, free-T3,
IGF-1, mean 24-h GH levels (sampled six times over the day) are
in the normal range (Figure 1). This absence of undernutrition
markers is in line with the low levels of leptin, still higher than in
AN, and with preserved circadian cycle (13). A girl with low BMI
and normal free-T3 or IGF-1 is not a R-AN.
Anorexia nervosa is associated with well-known hypothalamus–
pituitary–peripheral axis changes/disturbances such as “pseudo-
Cushing syndrome” and hypogonadism. Indeed, the excess of the
hypothalamic–pituitary–adrenal (HPA) axis activity includes high
CRF (14), increased circadian cortisol levels (15), and rapid escape
of cortisol from suppression in response to i.v. dexamethasone
(16). Nevertheless, R-AN patients display no clinical Cushing-like
features and is considered as a“pseudo-Cushing syndrome.”These
abnormalities regress after refeeding (17).
Restrictive anorexia nervosa amenorrhea, the only somatic trait
in the DSM IV classification, is the consequence of blunted HPG
axis associating low estradiol (18), low free testosterone levels
(8), and absence of LH pulsatility (19). This low GnRH activ-
ity seems to be dependent on multiple neuropeptides/amino acids
influences including opioid (20), gabaergic (21), or serotoninergic
activity (22) changes. Refeeding restores menses only in 55–100%
of R-AN women (23–25). GnRH pump is the current validated
treatment to restore LH pulsatility and to stimulate ovulation (26).
This treatment leads to ovulation in 100% of cases, most often
between day 10 and 14, and to pregnancy in 55% of cases after 6
stimulations (unpublished data).
Oppositely, normal HPA axis activity suggested by normal six-
point (8, 12, 16, 20, 24, 04 h) circadian levels of cortisol was found
in CT subjects matched for BMI and gender. Functional HPG axis
was also attested by normal LH, FSH, estradiol, and free testos-
terone plasma level without oral contraception, and preserved
fertility (13). A young adult girl with low BMI and normal menses
without pills, and normal hormonal profile is not a R-AN.
The alteration of bone quality in AN, a consequence to under-
nutrition and hormonal abnormalities, is widely accepted. Loss
of bone density, correlated with the duration of low BMI (27)
and explained by a bone turnover uncoupling (28) leads to
increased fractures risk (29), also related with some genetic distur-
bances (30). An important issue comes from the lack of treatment
to increase bone mineral density, except refeeding. Hormonal
deficiency supplementation with IGF-1 (31), classical treatment
with bisphosphonates (32), or PTH administration (33) are not
approved. The role of estradiol in osteoporosis treatment is world-
wide accepted, but in R-AN the supplementation is non-effective
(34). The association of two hormonal supplementations without
side effects such as SDHA and estradiol seems to be effective (35,
36). However, all authors agree on the interest to treat earlier in
order to preserve and not to restore bone mineral density.
Bone loss with 44% of osteopenia is also found in 20 years
old CT subjects (37). Oppositely to the bone uncoupling seen
in R-AN, bone turnover is balanced in CT, with normal bone
formation (normal circadian osteocalcin profile) and bone resorp-
tion (normal plasma circadian CTX profile). Furthermore, bone
microarchitecture measured by pQCT is different (37). Combined
normal bone marker and specific microarchitecture profile are
other arguments to differentiate CT from R-AN and to avoid a
misdiagnosis.
While low food intake characterizes R-AN subjects, equilibrated
energy balance was noticed in CT (38). Food restriction behav-
ior of R-AN patients was found to be in opposition with the
theoretical action of most of the appetite regulating hormones.
Orexigenic gastric hormone ghrelin and the related gene derived
peptide obestatin are elevated in all studies without orexigenic
effect (13, 39). Ghrelin gene variants (40) or circulating antibodies
(41) are proposed to explain the“ghrelin-resistance.” Interestingly,
a normal ghrelin level is found in lean anorectic patients (AN)
with bingeing and in normal weight bulimic patients. High ghre-
lin seems to be a mark of restrictive subtype of AN (restrictive
only and binging associated) (42). A recently discovered hypothal-
amic orexigenic peptide called 26 RFa is also increased in R-AN,
and oppositely normal in CT (43). These hormones act through
Anorexia nervosa Cons!tu!onal thinness
BMI  ≤ 17,5 kg/m²
Presence of ea!ng disorders No ea!ng disorders; de-restric!on
Psychological disorders No psychological disorders
Amenorrhea Physiological menses
Hormonal abnormali!es= undernutri!on
T3 ↓, lep!ne↓, IGF-1 ↓, GH ↑
Cor!sol↑, ACTH ↑, 17 β E2 ↓, LH ↓, FSH ↓
No hormonal abnormali!es
= no sign of undernutri!on
Blunted fat mass Diminished fat mass 
Nega!ve energy balance Equilibrated / posi!ve energy metabolism
Weight loss / broken weight growth curve Stable weight within lower percen!le of growth curve
FIGURE 1 | Psychiatric, hormonal, and energy balance differences between CT andAN.
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the orexigenic neuron and peptide NPY. Conflicting results were
reported on pre-prandial plasma NPY (39). A low-circulating NPY
could explain the non-efficacy of orexigenic hormones. Recent
work showed role of NPY was more complex (44). These results
need confirmation by circadian assessment of NPY levels. NPY
data are not available in CT yet.
In CT, ghrelin and obestatin are in a normal range (13, 39).
Therefore, normal ghrelin levels in a pure R-AN patient are ques-
tionable. In this case, misdiagnosis of CT or purging type AN
should be discussed (42).
Studies on anorexic appetite regulating hormones as PYY and
GLP-1 in AN present with conflicting results (11, 45, 46). PYY level
in R-AN was found in normal range in our experience (11), but
elevated in another study (47), perhaps due to the misdiagnosis
of CT. Indeed, we reported in CT a high-PYY level throughout
the day (08, 12, 16, 20, 24, 04 h) (11). CT’s leptin was found lower
than in controls but higher than in R-AN with preserved circadian
variation. Finally, low level of leptin, another anorexic peptide,
found in all R-AN studies (13, 48) is probably more informative
on the fat mass than on the eating behavior. Discrepancies found
in appetite regulating hormones are in line with differences found
in questionnaires measuring restrained eating behavior (DEBQ)
or shape concern (EDE). Many questionnaires were proposed for
eating disorders phenotyping. EDI questionnaire is a self-report
questionnaire used to assess the presence of eating disorders,
anorexia nervosa both restricting and binge-eating/purging type
(49). EDE questionnaire deals with the frequency in which the
patient engages in behaviors indicative of an eating disorder over
a 28-day period (restraint, eating, shape, weight concern) (50),
DEBQ was developed to measure emotional external and restrain
eating (51). All of these psychological scales present pathological
scores in AN but not in CT. Moreover, we found an unrestrained
eating behavior in CT when compared to controls (3).
For the same, low BMI, anorectic behavior, and adaptive
appetite regulating hormone characterizes R-AN patients and
distinguishes them from CT patients.
Finally, genetic pathophysiologic role in AN was proposed
throughout polymorphism gene studies (52) or familial histories
of disease (53). Recently, two studies reported a tendency to the
gene hypothesis without the statistical significantly in 421 probants
for the first and 1606 probants for the second (54, 55). Significant
ratio of chromosome 16p11.2 region duplications was previously
noticed in lean patients with autism or schizophrenia (56), with-
out any argument to relate these results to leanness rather than to
psychiatric disorders. No genetic signature can be proposed at this
moment for the CT patients despite the family pedigree (38). Some
studies are in progress but no results are available. Along with all
these data on genetic approach, it is important to underline the role
of lean subjects’ phenotyping within these large cohorts’ studies.
DISCUSSION
This review focused on biological differences between R-AN and
CT. As CT display specific clinical features and normal hormonal
parameters, the misdiagnosis between CT and R-AN is no longer
permitted. A very thin girl who claims a normal diet should be
heard and not considered as a “liar” AN patient. A biological
assessment including leptin, free-T3, and IGF-1 is proposed in
order to avoid a misdiagnosis.
This review also focused on conflicting literature data reported
in R-AN. Because of the clinical or biological heterogeneity of
patients selected for the studies, publications results cannot always
be compared and could explained the conflicting data. Therefore,
straight and objective classification also called “phenotyping” is
required in clinical research in order to obtain better compara-
ble symptoms. For example, the definition shift between DSM IV
and DSM5 changes the developing risk of AN, double in a dancer
population (57) or in general population (58). Biological assess-
ment including hormonal, nutritional markers, neuroimaging, or
questionnaires could help on AN phenotyping. Currently, no bio-
logical determination or questionnaire evaluations are required
for AN definition in DSM5.
In conclusion, CT represents a well-defined real state of low
BMI associating a real weight gain desire, normal nutritional
markers except for a mild decreased leptin, a constitutive appetite
regulating hormone profile, the presence of menses in young
women and low bone mass. While CT diagnosis is still poorly
known, the new DSM5 AN definition proposing only psycho-
logical traits and no organic symptom is warring. In line with
mentioned somatic differences, we advocate complementary bio-
logical markers in AN definition in order to avoid the misdiagnosis
between AN and CT.
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